|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Emerging vaccine nanotechnology: From defense against infection to sniping cancer显示文摘Looking retrospectively at the development of humanity, vaccination is an unprecedented medical landmark that saves lives by harnessing the human immune system. During the ongoing coronavirus disease 2019(COVID-19) pandemic, vaccination is still the most effective defense modality. The successful clinical application of the lipid nanoparticle-based Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines highlights promising future of nanotechnology in vaccine development. Compared with conventional vaccines, nanovaccines are supposed to have advantages in lymph node accumulation,antigen assembly, and antigen presentation;they also have, unique pathogen biomimicry properties because of well-organized combination of multiple immune factors. Beyond infectious diseases, vaccine nanotechnology also exhibits considerable potential for cancer treatment. The ultimate goal of cancer vaccines is to fully mobilize the potency of the immune system as a living therapeutic to recognize tumor antigens and eliminate tumor cells, and nanotechnologies have the requisite properties to realize this goal.In this review, we summarize the recent advances in vaccine nanotechnology from infectious disease prevention to cancer immunotherapy and highlight the different types of materials, mechanisms, administration methods, as well as future perspectives. | Chan Feng Yongjiang Li Bijan Emiliano Ferdows Dylan Neal Patel Jiang Ouyang Zhongmin Tang Na Kong Enguo Chen Wei Tao | 2022 | Acta Pharmaceutica Sinica B2022，12，5： | 4 |
| 2 | Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer显示文摘gonadal 睾丸激素合成的抑制首先代表标准为变形前列腺癌症的治疗的线治疗。在得阉割抵抗的前列腺癌症(CRPC ) 的病人的多数,然而,通过自己在肾上腺或在肿瘤以内生产的雄激素检测雄激素受体(AR ) 的坚持的激活是可能的。Abiraterone 醋酸盐作为 17 α 与活动作为双功能的细胞色素 P450 酶 CYP17 的一个不可逆的禁止者被开发; -hydroxylase 和 17,20-lyase。CYP17 为从胆固醇的 nongonadal 雄激素的生产是必要的。基于与 abiraterone 和泼尼松对泼尼松在全面幸存(OS ) 显示出重要改进的阶段 III 试用,在 2011 的 abiraterone 的规章的赞同代表了指向 AR 为与 CRPC 在人改进结果是必要的原则的证明。 17 α 的抑制;由 abiraterone 的 -hydroxylase 由于垂体的调停皮质醇的抑制的损失导致在上游的 mineralocorticoids 的累积促肾上腺皮质的荷尔蒙( ACTH ),为 17,20-lyase 为 CYP17 禁止者的开发向一个基本原理提供增加的特性( orteronel , galeterone 和 VT-464 )没有外长的 corticosteroids ,那能潜在地被管理。在这篇文章,我们考察 abiraterone 和另外的 CYP17 禁止者的发展;有 abiraterone 的最近的研究在 quality-of-life,反应的潜在的早预言者,并且关于另外的代理人的 abiraterone 的最佳的定序上通知我们的理解象药效果那样的临床的参数;并且提供卓见进抵抗机制给导致临床的试用,药联合设计了延长 abiraterone 利益或恢复 abiraterone 活动的 CYP17 禁止者的翻译研究结果。 | Mark N Stein | 2014 | Asian Journal of Andrology2014，16，3： | 3 |
| 3 | Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis显示文摘 | Min Jun Celine Foote Jicheng Lv Bruce Neal Anushka Patel Stephen J Nicholls Diederick E Grobbee Alan Cass John Chalmers Vlado Perkovic | 2010 | The Lancet . 2010 (9729)2010，，9729： | 2 |
| 4 | Changes in efficiency and resource utilization after increasing experience with double balloon enteroscopy显示文摘AIM:To investigate changes in efficiency and resource utilization as a single endoscopist's experience increased with each subsequent 100 double balloon enteroscopy(DBE) procedures.METHODS:We reviewed consecutive DBE procedures performed by a single endoscopist at our center over 4 years.DBE was employed when the clinician deemed the procedure was needed for disease management.The approach(oral,anal or both) was chosen based on suspected location of the target lesion.All DBE was performed in a standard endoscopy room with a portable fluoroscopy unit.Fluoroscopy was used to aid in shortening the small intestine and reducing bowel loops.For oral DBE,measurements were taken from the incisors.For anal DBE,measurements were taken from the anal verge.Enteroscopy continued until the target lesion was reached,until the entire small intestine was examined,or until no further progress was deemed possible.The length of small intestine examined(cm),procedure duration(min),and fluoroscopy time(s) were analyzed for sequential groups of 100 DBE.Sub-groups of diagnostic and therapeutic procedures were analyzed using multivariable linear regression.RESULTS:802 consecutive DBE procedures were analyzed.For oral DBE,median [interquartile range(IQR)] length of small bowel examined was 230.8 cm(range:210-248 cm) and for anal DBE was 143.5 cm(range:100-180 cm).No significant increase in length examined was noted for either the oral or anal approach with advancing position in series.In terms of duration of procedure,the median(IQR) for oral DBE was 86 min(range:71-105 min) and for anal DBE was 81.3 min(range:67-105 min).When comparing by the position in series,there was a significant(P value < 0.001) decrease in procedure duration for both upper and lower procedures with increasing experience.Median(IQR) time of exposure to fluoroscopy for oral DBE was 190 s(114-275) compared to anal DBE which was 196.4 s(312-128).This represented a significant(P value < 0.001) decrease in the amount of fluoroscopy used with increasing position in series.For both oral and anal DBE,fluoroscopy time was reduced by greater than 50% over the course of 802 total procedures performed.Sub-group analysis was conducted on therapeutic and diagnostic groups.Out of 802 procedures,a total of 434 were considered therapeutic.Argon plasma coagulation was by far the most common therapeutic intervention performed.There was no evidence of a difference in length examined or fluoroscopy exposure among oral DBE for diagnostic and therapeutic procedures,P = 0.91 and P = 0.32 respectively.The median(IQR) for length was 235 cm(range:178-280 cm) for diagnostic vs 230 cm(range:180-275 cm) for therapeutic procedures;additionally,fluoroscopy time median(IQR) was 180 s(range:110-295 s) and 162 s(range:102-263 s) for no intervention and intervention.However,there was a significant difference in procedure duration among oral DBE(P < 0.001).The median(IQR) was 80 min(range:60-97 min) and 94 min(range:77-110 min) for diagnostic and therapeutic interventions respectively.CONCLUSION:For a single endoscopist,increased DBE experience with number of performed procedures is associated with increased efficiency and decreased resource utilization. | Neal C Patel William C Palmer Kanwar R Gill David Cangemi Nancy Diehl Mark E Stark | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，3： | 2 |
| 5 | Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis显示文摘 | Min Jun Celine Foote Jicheng Lv Bruce Neal Anushka Patel Stephen J Nicholls Diederick E Grobbee Alan Cass John Chalmers Vlado Perkovic | 2010 | The Lancet2010，，9729： | 1 |
| 6 | Topology Opti- mization Using a Hybrid Cellular Automaton Method with lx~eal Control Rules 显示文摘 | Tovar Andres Patel Neal M Niebur Glen L | 2006 | Journal of Mechanical Design2006，128，12： | 1 |
| 7 | Comparison of techniques for transsphenoidal pituitary surgery显示文摘 | Neal JG Patel SJ Kulbersh JS | 2007 | Am J Rhinol2007，21，2： | 1 |
| 8 | Comparison of techniques for transsphenoidal pituitary surgery 显示文摘 | Neal JG Patel S J Kulbersh JS | 2007 | Am J Rhino12007，21，2： | 1 |
| 9 | Prevention of erectile dysfunction after radiotherapy for prostate cancer显示文摘与增加前列腺癌症(PCa ) 的审查诊断和治疗,许多注意被给了激进的前列腺切除术(RP ) 或放射疗法(RT ) 引起的病态。任何一个治疗的最普通的副作用之一近似是可勃起的机能障碍(编辑).1, 40% 病人将为 PCa 在 RT 以后经历编辑。 post-RT 编辑在病人和搭挡 psychosocial function.2 象减少一样引起有癌症治疗的重要耐心的不满在经历 RT 的病人,处理这个问题进行的 Pisansky et al.3 一未来,使随机化, 双blinded ,估计一个 phosphodiesterase enzyme-5 禁止者( PDE5i )的功效的控制安慰剂的试用, tadalafil ,为为 PCa 经历 RT 的病人的一项预防措施并且别在在控制和 treatm | Izak Faiena Neal Patel Allen D Seftel | 2014 | Asian Journal of Andrology2014，16，6： | 1 |
| 10 | Comparison of techniques for transsphenoidal pituitary surgery 显示文摘 | Neal JG Patel SJ Kulbersh JS | 2007 | AM J Rhinol2007，21，2： | 1 |
| 11 | Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus显示文摘 | Jun Hata Hisatomi Arima Peter M. Rothwell Mark Woodward Sophia Zoungas Craig Anderson Anushka Patel Bruce Neal Paul Glasziou Pavel Hamet Giuseppe Mancia Neil Poulter Bryan Williams Stephen MacMahon John Chalmers | 2013 | Circulation2013，，12： | 1 |
| 12 | Targeted Deletion of Metalloproteinase 9 Attenuates Experimental Colitis in Mice: Central Role of Epithelial-Derived MMP显示文摘 | Florencia E. Castaneda Baljit Walia Matam Vijay–Kumar Neal R. Patel Susanne Roser Vasantha L. Kolachala Mauricio Rojas Lixin Wang Gabriela Oprea Pallavi Garg Andrew T. Gewirtz Jesse Roman Didier Merlin Shanthi V. Sitaraman | 2005 | Gastroenterology2005，，6： | 1 |
| 13 | Integrating three-dimensional digital technologies tk)r comprehensive implant dentistry 显示文摘 | Neal Patel | 2010 | J Am Dent Assoe2010，141，： | 1 |
| 14 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge. | Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch | 2016 | World Journal of Gastroenterology2016，22，9： | 1 |
| 15 | Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs显示文摘AIM: To determine risk factors associated with hepatitis C virus(HCV) treatment failure after direct acting antivirals in patients with complex treatment histories.METHODS: All HCV mono-infected patients who received treatment at our institution were queried.Analysis was restricted to patients who previously failed treatment with boceprevir(BOC) or telaprevir(TVR) and started simeprevir(SMV) and sofosbuvir(SOF) ± ribavirin(RBV) between December 2013 and June 2014. Patients with human immunodeficiency virus(HIV)/HCV co-infection or patients who received a liver transplant in the past were excluded. Viral loads were recorded while on treatment and after treatment. Data collection continued until December,31 st 2014 when data analysis was initiated. Patients missing virologic outcomes data were not included in the analysis. Analysis of 35 patients who had virologic outcome data available resulted in eight patients who were viral load negative at the end of treatment with SMF/SOF but later relapsed. Data related to patient demographics,HCV infection,and treatment history was collected in order to identify risk factors shared among patients who failed treatment with SMF/SOF.RESULTS: Eight patients who were treated with the first generation HCV protease inhibitors BOC or TVR in combination with pegylated-interferon(PEG) and RBV who failed this triple therapy were subsequently retreated with an off-label all-oral regimen of SMV and SOF for 12 wk,with RBV in seven cases. Treatment was initiated before the Food and Drug Administration approved a 24-wk SMV/SOF regimen for patients with liver cirrhosis. All eight patients had an end of treatment response,but later relapsed. Eight(100%) patients were male. Mean age was 56(range,49-64). Eight(100%) patients had previously failed PEG/RBV dual therapy at least once in addition to prior failure with triple therapy. Total number of times treated ranged from 3-6(mean 3.8). Eight(100%) patients were male had liver cirrhosis as determined by Fibroscan or MRI. Seven(87.5%) patients had genotype 1a HCV. Seven(87.5%) patients had over 1 million IU/m L HCV RNA at the time of re-treatment.CONCLUSION: This study identifies factors associated with SMV/SOF treatment failure and provides evidence that twleve weeks of SMV/SOF/RBV is insufficient in cirrhotics with high-titer genotype 1a HCV. | Joshua Hartman Kian Bichoupan Neal Patel Sweta Chekuri Alyson Harty Douglas Dieterich Ponni Perumalswami Andrea D Branch | 2015 | World Journal of Gastroenterology2015，21，43： | 1 |
| 16 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 17 | Measurement of polypectomy rate by using administrative claims data with validation against the adenoma detection rate显示文摘 | Neal C. Patel Rafiul S. Islam Qing Wu Suryakanth R. Gurudu Francisco C. Ramirez Michael D. Crowell Douglas O. Faigel | 2012 | Gastrointestinal Endoscopy2012，，： | 1 |
| 18 | 725 Measurement of Polypectomy Rate Using Administrative Claims Data With Validation Against the Adenoma Detection Rate显示文摘 | Neal C. Patel Sameer Islam Qing Wu Suryakanth Gurudu Francisco C. Ramirez Michael D. Crowell Douglas O. Faigel | 2012 | Gastrointestinal Endoscopy2012，，4： | 1 |
| 19 | Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial显示文摘 | G.-D. Batty Q. Li R. Huxley S. Zoungas B.-A. Taylor B. Neal B. de Galan M. Woodward S.-B. Harrap S. Colagiuri A. Patel J. Chalmers | 2011 | European Psychiatry2011，，： | 1 |
| 20 | Regulation of corticoid and serotonin receptor brain system following early life exposure of glucocorticoids:long term implications for the neurobiology of mood显示文摘 | Vázquez DM Neal CR Jr Patel PD | | 0，，03： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员